HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties SHANGHAI, Sept. 29, 2026 /PRNewswire/ -- Hengrui Pharma...
Hence then, the article about hengrui pharma and novo enter exclusive license agreement for once weekly oral glp 1 gip dual receptor agonist hrs 1596 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596 )
Also on site :
- AMD acquires startup cofounded by ‘godmother of AI’ Fei-Fei Li for $8.2 billion
- Fans Spot a Major Change to Taylor Swift’s ‘The Man’ Music Video During VMA Presentation — Easter Egg or Editing Error?
- In 2012, ‘Glee’ star Dianna Agron paid $1.05 million for a 1920s Hollywood Hills house; she sold it in 2016, and it is now listed at $2.7 million